TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01165034

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathlessness Support Service
Description: Patients randomised to the intervention group (IG) will be entered into the BSS in addition to standard best usual care. Expertise in the BSS will comprise of a palliative care consultant or specialist registrar (SpR), a respiratory medicine consultant or SpR with a specialist interest in breathlessness, a respiratory physiotherapist, an occupational therapist and a respiratory nurse specialist. Patients will see 12 health professionals per visit, and multidisciplinary team meetings will take place before and after each visit. Outpatient clinics will take place once per week. The timing of interventions and data collection has been designed to allow for short disease trajectories in patients with cancer and minimise patient burden, whilst allowing time for interventions to have the desired effect. Four weeks is considered to be the minimum length of pulmonary rehabilitation programmes that give a clinically significant benefit.
Study: NCT00776399

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung radiofrequency ablation
Description: A radiofrequency (RF) electrode is placed in the lung metastasis percutaneously. RF energy is applied to the tumor to induce coagulation necrosis.
Study: NCT04169464

Intervention type: DRUG
Group type: OTHER
Intervention: Sofosbuvir Oral Product
Description: to investigate the drug effect on renal function and insulin resistance
Study: NCT00202696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalmefene
Description: Nalmefene HCl film-coated tablets administered orally, twice daily, for total daily dosage of 40 or 80 mg, for 5 weeks (following a 2-week titration period).
Study: NCT02584868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution
Description: Peri-operative fluid replacement therapy (max 40ml/kg/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyethyl starch 130/0.4 in 0.9% sodium chloride
Description: Peri-operative fluid replacement therapy (max 40ml/kg/day)
Study: NCT02814695

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vit E
Description: 0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (2 mg/ml) Vitamin E and incubated at 37o C for 30 minutes.
Study: NCT02814695

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yeast
Description: 0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (20 mg/ml) yeast extraction and incubated at 37o C for 30 minutes.
Study: NCT00202696

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo tablets, administered orally, twice daily for 5 weeks (following a 2-week titration period).
Study: NCT03809273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yangxinshi
Description: Yangxinshi pill 3 pills /tid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimetazidine
Description: Trimetazidine 20mg/tid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yangxinshi mimic
Description: Yangxinshi mimic tablets 3 pills /tid
Study: NCT03018808

Intervention type: PROCEDURE
Intervention: Blood test
Description: Blood samples will be collected at indicated time points

Intervention type: PROCEDURE
Intervention: Blood test
Description: Blood samples will be collected at indicated time points
Study: NCT02814695

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vit C 1
Description: 0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (0.02 mg/ml) Vitamin C and incubated at 37o C for 30 minutes.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vit C 2
Description: 0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (0.04 mg/ml) Vitamin C and incubated at 37o C for 30 minutes.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vit C 3
Description: 0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (0.06 mg/ml) Vitamin C and incubated at 37o C for 30 minutes.
Study: NCT01803711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desvenlafaxine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 Fatty acids

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Omega 3 fatty acid supplement)
Study: NCT03809273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimetazidine mimic
Description: Trimetazidine mimic tablets 20mg/tid
Study: NCT01645085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCC-based 13% drug loaded tablets
Description: 50mg tablets, dosed as 2 tablets (100mg total)
Study: NCT01768949

Intervention type: DEVICE
Group type: OTHER
Intervention: Echocardiography
Description: In the study RVSTAR, all the patients included will undergo an echocardiography in order to find an echocardiographic criterion predictive of the inefficacy and/or unsafeness of recruitment maneuver.
Study: NCT04024826

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EFP
Description: This group will perform the Resistance training intervention on day 4 of the menstrual cycle, which corresponds to the mid of early follicular phase.
Study: NCT01645085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol-based 38% drug-loaded tablet
Description: One 100mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCC-based 13% drug loaded tablets
Description: 3 tablets (150mg total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol-based 38% drug-loaded tablet
Description: One 150 mg tablet
Study: NCT03056807

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 25° head-up position
Description: Angle person is positioned for procedure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 55° head-up position
Description: Angle person is positioned for procedure.
Study: NCT02907671

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: carpal tunnel corticoanesthetic injection
Description: Different Injection Sites (between the flexot tendons or around the median nerve with hydrodissection)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: carpal tunnel corticoanesthetic injection
Description: Different Injection Sites (between the flexot tendons or around the median nerve with hydrodissection)
Study: NCT03018808

Intervention type: OTHER
Intervention: anthropometric measures
Description: Anthropologic measures will be performed.

Intervention type: OTHER
Intervention: anthropometric measures
Description: Anthropologic measures will be performed.
Study: NCT04467632

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Validation of the mobility assessment by IMU wearable sensors
Description: The validity of the mobility assessment by IMU wearable sensors will be verified in Work Package 3.~It will be defined as the accuracy of the machine learning algorithm to predict patients' motor status compared to the motor status assessed at clinical examination by means of the MDS-UPDRS-III scale and the Fit test. Prediction by machine learning will be compared with the MDS-UPDRS-III total score and with the 3.14 item (global clinical impression of mobility) of the same scale.~The patients will be asked to perform all the motor tasks of the MDS-UPDRS-III scale and the finger tapping test (Fit test) with both hands wearing the IMU system. A subset of minimal motor tasks allowing good prediction of the patient's motor status by the machine learning algorithm will then be selected for Work Package 4.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Testing in real-life conditions at patients' home in a small group of subjects
Description: Baseline Phase B1: Observation phase: 1-week wrist actigraphy and sleep diary to assess habitual activity/rest routines.~B2: Nocturnal sleep consolidation phase: 2 weeks: timed light exposure, constant sleep/wake routine and sleep restriction of 1 hour/night (based on habitual activity).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Testing in real-life conditions at patients' home in a small group of subjects
Description: Intervention phase~* Phase A (11 days): subjects will receive one hour of morning and afternoon light exposure twice a day:~  * Day #1: baseline assessment of outcome measures;~ * Days #2 to #6: bright light in the morning (active treatment) + dim light in the afternoon (placebo), to progressively advance circadian phase of 30' per day (phase advance of 2.5 hours obtained at day 6);~ * Days #7 to #11: dim light in the morning + bright light in the afternoon to revert the circadian phase to the baseline of 30' per day.~* Washout: 6 days. No intervention during this phase, to stabilise the reverted circadian rhythm to baseline, for phase B to be held at the same conditions as phase A.~* Phase B (11 days): similar as in phase A:~  * Day #1: similar as in phase A;~ * Days #2 to #6: reverted conditions compared to phase A.~ * Days #7 to #11: reverted conditions compared to phase A.
Study: NCT02823041

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: 24 weeks of systematic computerized cognitive training, 4 hours per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The 2nd 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. A weekly one-hour Bridging Skills Group is designed to aid generalization of training to everyday life situations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: 24 weeks of systematic computerized cognitive training, 4 hours per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The 2nd 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. A weekly one-hour Bridging Skills Group is designed to aid generalization of training to everyday life situations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Aerobic exercise occurs as two 45-minute sessions at the clinic and two 30-minute sessions at home weekly. Exercise involves an adaptation of interval training, including a variety of calisthenics that can be done without specialized equipment. Intensity of aerobic exercise is tailored to maintain an individualized target heart rate zone and is monitored by a heart rate recorder.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Case management and supportive psychotherapy
Description: An individual therapist will provide weekly case management and therapy targeting the individual psychological problems and everyday functioning needs of the patient

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case management and supportive psychotherapy
Description: An individual therapist will provide weekly case management and therapy targeting the individual psychological problems and everyday functioning needs of the patient

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Placement and Support
Description: An job/school specialist will use the Individual Placement and Support model to help participants return to school or work and provide ongoing outreach support.
Study: NCT03018808

Intervention type: OTHER
Intervention: Oximetry
Description: Digital pulse oximeter on the index finger after five minutes rest and before receiving bronchodilator for spirometry will be used to measure the pulse arterial oximetry. The average of three measurements at 10 second intervals will be recorded. The heart rate will be provided by the pulse oximeter.

Intervention type: OTHER
Intervention: Oximetry
Description: Digital pulse oximeter on the index finger after five minutes rest and before receiving bronchodilator for spirometry will be used to measure the pulse arterial oximetry. The average of three measurements at 10 second intervals will be recorded. The heart rate will be provided by the pulse oximeter.
Study: NCT01490931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Nasal Spray
Description: 15.75 mg nasal spray delivery to each nostril no more than every six hours
Study: NCT00307034

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' 10-valent pneumococcal conjugate vaccine.
Description: Intramuscular injection, 3 or 4 doses (2-4-11 or 2-3-4-11 months of age schedule).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' 10-valent pneumococcal conjugate vaccine.
Description: Intramuscular injection, 3 or 4 doses (2-4-11 or 2-3-4-11 months of age schedule).
Study: NCT02823041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support
Description: An job/school specialist will use the Individual Placement and Support model to help participants return to school or work and provide ongoing outreach support.
Study: NCT02307539

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psychosocial Assessment and Care
Description: Undergo PCPI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Therapy
Description: Undergo PCPI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Undergo QOL assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Undergo questionnaire administration
Study: NCT01064219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human chorionic gonadotrophin
Description: intrauterine injection of 100 IU hCG followed by endometrial biopsy .
Study: NCT02195934

Intervention type: OTHER
Group type: OTHER
Intervention: Standard (blonde) orange juice
Description: Consumption of 500ml standard (blonde) orange juice daily for 28 days

Intervention type: OTHER
Group type: OTHER
Intervention: Standard (blonde) orange juice
Description: Consumption of 500ml standard (blonde) orange juice daily for 28 days

Intervention type: OTHER
Group type: OTHER
Intervention: Blood orange juice
Description: Consumption of 500ml blood orange juice daily for 28 days

Intervention type: OTHER
Group type: OTHER
Intervention: Blood orange juice
Description: Consumption of 500ml blood orange juice daily for 28 days
Study: NCT03312868

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic Body Radiotherapy
Study: NCT00307034

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa.
Description: Intramuscular injection, 3 doses (2-4-11 months of age schedule).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa.
Description: Intramuscular injection, 3 doses (2-4-11 months of age schedule).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV/Hib.
Description: Intramuscular injection, 3 doses (2-4-11 months of age schedule).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV/Hib.
Description: Intramuscular injection, 3 doses (2-4-11 months of age schedule).
Study: NCT04465630

Intervention type: DEVICE
Group type: OTHER
Intervention: OMNI® Surgical System
Description: Ab-interno transluminal viscoelastic delivery and trabeculotomy performed with the OMNI Surgical System
Study: NCT03880760

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: L. johnsonii MH-68, B. animalis subsp. lactis CP-9 and L. salivarius AP-32
Description: Taking 1 L. johnsonii MH-68, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics capsule twice a day before meals for six months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taking 1 placebo capsule twice a day before meals for six months.
Study: NCT02754466

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subjective vs objective criteria in selective excavation
Description: Subjective vs Objective criteria (Polymer burs) to perform selective excavation of dentin caries in deep lesions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glass-ionomer vs Bulk fill composites in the ART approach
Description: High-viscosity glass-ionomer vs Bulk fill composite to restore shallow and medium depth dentin lesions using the ART approach
Study: NCT03560349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine HCl Gel 2%
Description: Patients will be prescribed a regimen of 1 g acetaminophen q 8hrs alternating with 600 mg ibuprofen q 6 hours. In addition they will be instructed to continue oral fluid hydration and minimal activity for 24 hours.~At 2-hours following the SPG blockade an EBP will be offered to patients. Patient will also be informed that they can request an EBP at any time. The SPG blockade will be performed twice daily in the hospital and twice daily at home, by the patient. The patient will also be informed, if that at anytime, they would like an EBP, it can be provided.~While the study is being conducted, patients will not be offered a SPG block unless enrolled in the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: Patients will be prescribed a regimen of 1 g acetaminophen q 8hrs alternating with 600 mg ibuprofen q 6 hours. In addition they will be instructed to continue oral fluid hydration and minimal activity for 24 hours.~At 2-hours following the SPG blockade an EBP will be offered to patients. Patient will also be informed that they can request an EBP at any time. The SPG blockade will be performed twice daily in the hospital and twice daily at home, by the patient. The patient will also be informed, if that at anytime, they would like an EBP, it can be provided.~While the study is being conducted, patients will not be offered a SPG block unless enrolled in the study.
Study: NCT03052322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB11022
Description: Participants received MSB11022 (modified buffer and stabilizer) subcutaneously at dose of 40 milligram (mg) every other week from Day 1 up to Week 48.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-Humira
Description: Participants received EU-Humira subcutaneously at dose of 40 mg every other week from Day 1 up to Week 48.
Study: NCT04331444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM
Description: Using the CGM during the entire study period of 12 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM
Description: Using the CGM during the entire study period of 12 months.
Study: NCT04024826

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LFP
Description: This group will perform the Resistance training intervention on day 11 of the menstrual cycle, which corresponds to the mid of late follicular phase.
Study: NCT04331444

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: training course
Description: The participants in the three groups will attend a three-hour training course with different content depending on the group allocation. The aim of this training course is to ensure that the participants have the knowledge, support and confidence to work collaboratively with their HCPs to increase TIR and decrease HbA1c.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: training course
Description: The participants in the three groups will attend a three-hour training course with different content depending on the group allocation. The aim of this training course is to ensure that the participants have the knowledge, support and confidence to work collaboratively with their HCPs to increase TIR and decrease HbA1c.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: training course
Description: The participants in the three groups will attend a three-hour training course with different content depending on the group allocation. The aim of this training course is to ensure that the participants have the knowledge, support and confidence to work collaboratively with their HCPs to increase TIR and decrease HbA1c.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-support
Description: The peer-support will be facilitator-led by the primary investigator with peer exchange in group sessions (3 sessions over the study period, 3 hours per session) with 6-8 participants in every group.
Study: NCT01948986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: Single oral administration of 3 X 5 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: Single oral administration of 3 X 5 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: Single oral administration of 3 X 5 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: Single oral administration of 3 X 5 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: Single oral administration of 3 X 5 mg tablets.
Study: NCT03479463

Intervention type: BIOLOGICAL
Intervention: Dehydrated human amnion/chorion membrane
Description: Laryngectomy/pharyngectomy patched with dehydrated human amnion chorion allograft
Study: NCT01519986

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Supplement of vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Supplement of vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Supplement of vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT03893474

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: OCT
Description: Optical Coherence Tomography of study eye.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: OCT
Description: Optical Coherence Tomography of study eye.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Visual Acuity
Description: Visual acuity measured by ETDRS

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Visual Acuity
Description: Visual acuity measured by ETDRS
Study: NCT03996161

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient position
Description: After the induction of anesthesia, mask ventilation is performed in the supine and semi-sitting position in a cross-over, randomized order.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: patient position
Description: After the induction of anesthesia, mask ventilation is performed in the supine and semi-sitting position in a cross-over, randomized order.